ArticleHaematologica2014

Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma.

Thomas E Witzig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.